[
  {
    "ts": "2025-11-06T05:38:45+00:00",
    "headline": "Gilead Sciences’s Q3 Earnings Call: Our Top 5 Analyst Questions",
    "summary": "Gilead Sciences’ third quarter was marked by strong sales growth in its HIV and liver disease portfolios, but the market responded negatively due to ongoing concerns about oncology revenue and broader commercial headwinds. Management credited the quarter’s performance to robust demand for Biktarvy and Descovy, as well as the successful launch of Yeztugo for HIV prevention and Livdelzi for liver disease. CEO Daniel O’Day specifically highlighted the company’s “disciplined operating expense manage",
    "url": "https://finance.yahoo.com/news/gilead-sciences-q3-earnings-call-053845749.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "dd6bc9c8-d924-3413-b44c-330529de51f5",
      "content": {
        "id": "dd6bc9c8-d924-3413-b44c-330529de51f5",
        "contentType": "STORY",
        "title": "Gilead Sciences’s Q3 Earnings Call: Our Top 5 Analyst Questions",
        "description": "",
        "summary": "Gilead Sciences’ third quarter was marked by strong sales growth in its HIV and liver disease portfolios, but the market responded negatively due to ongoing concerns about oncology revenue and broader commercial headwinds. Management credited the quarter’s performance to robust demand for Biktarvy and Descovy, as well as the successful launch of Yeztugo for HIV prevention and Livdelzi for liver disease. CEO Daniel O’Day specifically highlighted the company’s “disciplined operating expense manage",
        "pubDate": "2025-11-06T05:38:45Z",
        "displayTime": "2025-11-06T05:38:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "GILD Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7IhZSScYZ4CvnQJJpve_Dg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cv.0mSrHV7hG2Zeh2xc10A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-q3-earnings-call-053845749.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-q3-earnings-call-053845749.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]